Tabersonine

Natural Products

Akt; Apoptosis; Caspase; CDK; Cytochrome P450; Interleukin Related; NF-κB; NOD-like Receptor (NLR); p38 MAPK; PI3K

4°C (Powder, protect from light)

Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer[1][2][3].

DMSO: 25 mg/mL (ultrasonic)

Caspase 1; Caspase 8; CDK4; IL-1; NLRP3